Literature DB >> 12099723

Modification of myosin gene expression by imidapril in failing heart due to myocardial infarction.

Jingwei Wang1, Xueliang Liu, Bin Ren, Heinz Rupp, Nobuakira Takeda, Naranjan S Dhalla.   

Abstract

The beneficial effects of imidapril, an angiotensin converting enzyme (ACE) inhibitor were investigated on changes in myofibrillar ATPase as well as myosin heavy chain (MHC) content and gene expression due to myocardial infarction (MI). Three weeks after occluding the left coronary artery, rats were treated with or without imidapril (1 mg/kg/day), for 4 weeks. The infarcted hearts exhibited depressed rates of left ventricular (LV) pressure development (57+/-2.4% reduction) and pressure decay (55.5+/-1.6% reduction). LV myofibrillar Ca(2+) ATPase activity, unlike that in the right ventricle (RV), was decreased in the infarcted animals compared with controls (6.8+/-0.4 vs 10.3+/-0.6 micromol Pi/mg/hr). MHC alpha-isoform contents were decreased by 47 and 41% whereas those of MHC beta-isoform were increased by 823 and 1200% in the LV and RV due to MI, respectively. MHC alpha-isoform mRNA levels were decreased by 55 and 35% whereas those for MHC beta-isoform were increased by 50 and 30% in the infarcted LV and RV, respectively. Imidapril treatment partially prevented the changes due to MI in LV function (rate of pressure development, 24+/-2.3% reduction and rate of pressure decay, 14+/-1.8% reduction), myofibrillar Ca(2+) ATPase activity (8.2+/-0.7 micromol Pi/mg/hr), MHC protein content (alpha-MHC, 24% reduction and beta-MHC, 525% increase) and MHC gene expression (alpha-MHC, 18% reduction and beta-MHC, 15% increase). The results suggest that the beneficial effects of ACE inhibition on the failing heart are associated with improvements in myofibrillar ATPase activities as well as prevention of changes in MHC isozyme protein contents and their gene expression. Copyright 2002 Elsevier Science Ltd. All rights reserved. (c) 2002 Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12099723     DOI: 10.1006/jmcc.2002.2023

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  15 in total

Review 1.  Myofibrillar remodeling in cardiac hypertrophy, heart failure and cardiomyopathies.

Authors:  Jarmila Machackova; Judit Barta; Naranjan S Dhalla
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

2.  Imidapril treatment improves the attenuated inotropic and intracellular calcium responses to ATP in heart failure due to myocardial infarction.

Authors:  Harjot K Saini; Qiming Shao; Sorin Musat; Nobuakira Takeda; Paramjit S Tappia; Naranjan S Dhalla
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

Review 3.  Cardiac remodeling and subcellular defects in heart failure due to myocardial infarction and aging.

Authors:  Naranjan S Dhalla; Shashanka Rangi; Andrea P Babick; Shelley Zieroth; Vijayan Elimban
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

4.  Attenuation of changes in G(i)-proteins and adenylyl cyclase in heart failure by an ACE inhibitor, imidapril.

Authors:  R Sethi; Q Shao; N Takeda; N S Dhalla
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

5.  Changes in β-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system.

Authors:  Rajat Sethi; Qiming Shao; Bin Ren; Harjot K Saini; Nobuakira Takeda; Naranjan S Dhalla
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

6.  Partial prevention of changes in SR gene expression in congestive heart failure due to myocardial infarction by enalapril or losartan.

Authors:  Xiaobing Guo; Donald Chapman; Naranjan S Dhalla
Journal:  Mol Cell Biochem       Date:  2003-12       Impact factor: 3.396

7.  Renin-angiotensin blockade attenuates cardiac myofibrillar remodelling in chronic diabetes.

Authors:  Jarmila Machackova; Xueliang Liu; Anton Lukas; Naranjan S Dhalla
Journal:  Mol Cell Biochem       Date:  2004-06       Impact factor: 3.396

Review 8.  Small and large animal models in cardiac contraction research: advantages and disadvantages.

Authors:  Nima Milani-Nejad; Paul M L Janssen
Journal:  Pharmacol Ther       Date:  2013-10-15       Impact factor: 12.310

9.  Metabonomic strategy to the evaluation of chinese medicine compound danshen dripping pills interfering myocardial ischemia in rats.

Authors:  Xue Xin; Haimiao Zou; Ningning Zheng; Xinchun Xu; Yinmin Liu; Xiaoxian Wang; Hongbing Wu; Lina Lu; Jing Su; Mingfeng Qiu; Xiaoyan Wang
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-02       Impact factor: 2.629

10.  Metabolomic strategy for studying the intervention and the synergistic effects of the shexiang baoxin pill for treating myocardial infarction in rats.

Authors:  Li Xiang; Peng Jiang; Shuping Wang; Yaohua Hu; Xiaojun Liu; Rongcai Yue; Weidong Zhang; Runhui Liu
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-28       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.